Cardiff Oncology Insider Award: 40.6K Options to Director White

Rhea-AI Filing Summary

On 06/26/2025, Cardiff Oncology (CRDF) director Lale White reported the grant of 40,565 stock options at an exercise price of $3.16 under Form 4. The options become exercisable on 06/26/2026 and expire on 06/26/2035. The transaction code "A" confirms the award was acquired rather than purchased on the open market. Following this grant, White now holds 158,681 derivative securities (options) directly. No common shares were bought or sold, and no additional non-derivative activity was disclosed.

This filing appears to reflect routine director compensation designed to align insider incentives with shareholder interests. Because the award involves options—requiring future exercise—there is no immediate cash outflow or direct impact on outstanding share count.

Positive

• Director received 40,565 stock options, modestly increasing insider alignment with shareholders.

Negative

• None.

Insights

Financial Analyst

TL;DR Routine director option grant; modest size, neutral market impact.

The Form 4 discloses a standard compensation grant of 40,565 options to director Lale White at a $3.16 strike price. At current ownership of 158,681 options, the incremental award is not large enough to materially affect Cardiff Oncology’s float or insider ownership profile. Because the transaction is an acquisition via grant rather than an open-market buy, it provides limited bullish signalling. Overall, the event is neutral for valuation and liquidity and is unlikely to sway investor sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

White Lale

(Last) (First) (Middle)

C/O CARDIFF ONCOLOGY, INC.

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$3.16	06/26/2025		A		40,565		06/26/2026	06/26/2035	Common Stock	40,565	$0	158,681	D

Explanation of Responses:

	/s/ Lale White	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cardiff Oncology (CRDF) report in the latest Form 4?

Director Lale White was granted 40,565 stock options at a $3.16 exercise price.

Does the filing show any sale of CRDF common shares?

No. The Form 4 lists no dispositions of common stock.

How many derivative securities does Lale White now hold?

After the grant, White beneficially owns 158,681 stock options.

When do the new options granted to Lale White become exercisable and expire?

They become exercisable on 06/26/2026 and expire on 06/26/2035.

Is this Form 4 transaction likely to impact CRDF’s share count immediately?

No. Options only affect dilution upon exercise, so there is no immediate share impact.